OrbiMed’s Merck MRK Stock Holding History

OrbiMed’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-366,800	Closed	-$21.8M	–	137
2016 Q3	$21.8M	Buy	+366,800	New	+$21.4M	0.25%	71

Other funds holding MRK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed's MRK Position: Q1 2026 in Review

OrbiMed opened a new position in Merck (MRK) in Q1 2026: 663,400 shares worth $79.8M. The stake represents 1.58% of the portfolio and ranks #17 among its holdings. This is a return to the name: OrbiMed previously reported a position in MRK as recently as Q4 2024.

OrbiMed first reported a position in MRK in Q2 2013 and has held it in 41 quarters since. The position peaked at $363M in Q1 2017. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

OrbiMed held 663,400 shares of Merck worth $79.8M as of Q1 2026.
Merck was a new OrbiMed position in Q1 2026.
Merck made up 1.58% of OrbiMed's portfolio in Q1 2026, its #17 holding.
OrbiMed first reported a position in Merck in Q2 2013 and has held it in 41 quarters since.
OrbiMed's Merck position peaked at $363M in Q1 2017.
3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.